Oxytocin Protects against Stress-Induced Cell Death in Murine Pancreatic β-Cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Watanabe, Sayaka ^a   Wei, Fan Yan ^a   Matsunaga, Tomomi ^a   Matsunaga, Nanami ^a   Kaitsuka, Taku ^a   Tomizawa, Kazuhito ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIC AGENT; OXYTOCIN; OXYTOCIN RECEPTOR;

ANIMAL; CELL DEATH; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANIMALS; CELL DEATH; CELL SURVIVAL; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; OXYTOCICS; OXYTOCIN; RECEPTORS, OXYTOCIN; STRESS, PHYSIOLOGICAL;

EID: 84965154636     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25185     Document Type: Article

References (37)

1. Gimpl, G. & Fahrenholz, F. The oxytocin receptor system; structure, function, and regulation. Physiol Rev. 81, 629-683 (2001).
2. Dale, H. H. On some physiological actions of ergot. J Physiol. 34, 163-206 (1906).
3. Neumann, I. D. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol. 20, 858-865 (2008).
4. Insel, T. R. & Shapiro, L. E. Oxytocin receptors and maternal behavior. Ann N Y Acad Sci. 652, 122-141 (1992).
5. Argiolas, A. & Gessa, G. L. Central functions of oxytocin. Neurosci Biobehav Rev. 15, 217-231 (1991).
6. Bielsky, I. F. & Young, L. J. Oxytocin, vasopressin, and social recognition in mammals. Peptides. 25, 1565-1574 (2004).
7. Tomizawa, K. et al. Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat Neurosci. 6, 384-390 (2003).
8. Barberis, C., Mouillac, B. & Durroux, T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol. 156, 223-229 (1998).
9. Sanborn, B. M. et al. Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Adv Exp Med Biol. 449, 277-286 (1998).
10. Hanif, K., Lederis, K., Hollenberg, M. D. & Goren, H. J. Inability of oxytocin to activate pyruvate dehydrogenase in the Brattleboro rat. Science. 216, 1010-1012 (1982).
11. Amico, J. A., Finn, F. M. & Haldar, J. Oxytocin and vasopressin are present in human and rat pancreas. Am J Med Sci. 296, 303-307 (1988).
12. Dunning, B. E., Moltz, J. H. & Fawcett, C. P. Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP). Peptides. 5, 871-875 (1984).
13. Takayanagi, Y. et al. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport. 19, 951-955 (2008).
14. Camerino, C. Low sympathetic tone and obese phenotype in oxytocin-deficient mice. Obesity. 17, 980-984 (2009).
15. Antonelli, A. et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia. 45, 1298-1306 (2002).
16. Chen, J. et al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol. 176, 4590-4599 (2006).
17. Johnson, J. D. et al. Suppressed insulin signaling and increased apoptosis in CD38-null islets. Diabetes. 55, 2737-2746 (2006).
18. Jäger, S. et al. Breast-feeding and maternal risk of type 2 diabetes: a prospective study and meta-analysis. Diabetologia. 57, 1355-1365 (2014).
19. Aune, D., Norat, T., Romundstad, P. & Vatten, L. J. Breastfeeding and the maternal risk of type 2 diabetes: a systematic review and dose-response meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis. 24, 107-115 (2014).
20. Akerlund, M. et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol. 106, 1047-1053 (1999)
21. Kim, I., Xu, W. & Reed, J. C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 7, 1013-1030 (2008).
22. Darling, N. J. & Cook, S. J. The role of MAPK signaling pathways in the response to endoplasmic reticulum stress. Biochim Biophys Acta. 1843, 2150-2163 (2014).
23. Gonzalez-Reyes, A. et al. Molecular mechanisms underlying oxytocin-induced cardiomyocyte protection from simulated ischemia-reperfusion. Mol Cell Endocrinol. 412, 170-181 (2015).
24. Plante, E. et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology. 156, 1416-1428 (2015).
25. Alizadeh, A. M. et al. Oxytocin protects cardiomyocytes from apoptosis induced by ischemia-reperfusion in rat heart: role of mitochondrial ATP-dependent potassium channel and permeability transition pore. Peptides. 36, 71-77 (2012).
26. Wang, Y., Vera, L., Fischer, W. H. & Montminy, M. The CREB coactivator CRTC2 links hepatic ER stress and fasting gluconeogenesis. Nature. 460, 534-537 (2009).
27. Tu, S., Okamoto, S. I., Lipton, S. A. & Xu, H. Oligomeric Ab-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener. 9, 48 (2014).
28. de la Monte, S. M. & Wands, J. R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 6, 1101-1103 (2008).
29. Loup, F., Tribollet, E., Dubois-Dauphin, M. & Dreifuss, J. J. Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study. Brain Res. 555, 220-232 (1991).
30. McCarthy, M. M. & Altemus, M. Central nervous system actions of oxytocin and modulation of behavior in humans. Mol Med Today. 6, 269-275 (1997).
31. Blevins, J. E. & Baskin, D. G. Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans. Physiol Behav. S0031-9384(15), 00306-6 (2015)
32. Maejima, Y. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging. 3, 1169-1177 (2011).
33. Altirriba, J. et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology. 155, 4189-2041 (2014).
34. Zhang, H. et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One. 8, e61477 (2013).
35. Matsushita, H. et al. Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation. Neuroscience. 200, 13-18 (2012).
36. Wei, F. Y. et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest. 121, 3598-3608 (2011).
37. Ristow, M. et al. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest. 112, 527-534 (2003).